Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Long-Term Investments: 2015-2022

Historic Long-Term Investments for Assembly Biosciences (ASMB) over the last 4 years, with Dec 2022 value amounting to $18.6 million.

  • Assembly Biosciences' Long-Term Investments fell 33.52% to $18.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $18.6 million, marking a year-over-year decrease of 33.52%. This contributed to the annual value of $18.6 million for FY2022, which is 33.52% down from last year.
  • Per Assembly Biosciences' latest filing, its Long-Term Investments stood at $18.6 million for Q4 2022, which was up 56.17% from $11.9 million recorded in Q2 2022.
  • Assembly Biosciences' Long-Term Investments' 5-year high stood at $28.0 million during Q4 2021, with a 5-year trough of $2.2 million in Q2 2018.
  • For the 2-year period, Assembly Biosciences' Long-Term Investments averaged around $18.2 million, with its median value being $18.6 million (2022).
  • Data for Assembly Biosciences' Long-Term Investments shows a maximum YoY plummeted of 33.52% (in 2022) over the last 5 years.
  • Over the past 3 years, Assembly Biosciences' Long-Term Investments (Quarterly) stood at $2.2 million in 2018, then reached $28.0 million in 2021, then crashed by 33.52% to $18.6 million in 2022.
  • Its Long-Term Investments stands at $18.6 million for Q4 2022, versus $11.9 million for Q2 2022 and $23.5 million for Q1 2022.